TTI — Thiogenesis Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$30.56m
- CA$26.42m
- 38
- 11
- 57
- 27
Annual balance sheet for Thiogenesis Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | ARS | ARS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Cash and Short Term Investments | — | 7.08 |
| Net Total Accounts Receivable | ||
| Net Total Receivables | — | 0.085 |
| Prepaid Expenses | ||
| Total Current Assets | — | 7.24 |
| Total Assets | — | 7.24 |
| Payable / Accrued | ||
| Notes Payable / Short Term Debt | ||
| Total Current Liabilities | — | 1.71 |
| Total Long Term Debt | ||
| Total Debt | ||
| Total Liabilities | — | 1.71 |
| Common Stock | ||
| Retained Earnings (Accumulated Deficit) | ||
| Other Equity | ||
| Total Equity | — | 5.53 |
| Total Liabilities & Shareholders' Equity | — | 7.24 |
| Total Common Shares Outstanding |